Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus FOLFIRI vs FOLFIRI as first-line therapy for EGFR-expressing metastatic colorectal cancer
2004-000137-11Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Aug 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab in colorectal cancer (CRC) (2 arms), sponsored by Merck KGaA. Primary endpoint: Progression-free survival. Started Aug 2004; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2004-000137-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000137-11.